The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection.
about
The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert CommentaryDiagnostic accuracy of tests for Helicobacter pylori in an Alaska Native population.Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South KoreaHelicobacter pylori infection and markers of gastric cancer risk in Alaska Native persons: a retrospective case-control study.Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.Second-line rescue therapy of helicobacter pylori infection.Treatment of Helicobacter pylori infection: Past, present and futureHelicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development.Characterization of Helicobacter pylori cagA and vacA genotypes among Alaskans and their correlation with clinical disease.Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience"Rescue" regimens after Helicobacter pylori treatment failure.Review article: the global emergence of Helicobacter pylori antibiotic resistance.Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials.Fluoroquinolone-based protocols for eradication of Helicobacter pyloriTreatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.Emerging therapies for the treatment of Helicobacter pylori infections.Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012.Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.Trends in antimicrobial prescribing rates for Alaska Native and American Indian persons <18 years of age residing in the Anchorage region.Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.Should quinolones come first in Helicobacter pylori therapy?Rescue Therapy for Helicobacter pylori Infection 2012.Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents.Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany.Virulence genotypes and drug resistance of Helicobacter pylori from Vladivostok, Russia: another feature in the Far East.Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
P2860
Q26852409-D90228B4-8689-43F3-821B-1CD6EECEDECBQ30224839-6C582AEB-A99E-405D-AE4A-4F939E1A7F89Q33735315-FA0F4351-1CB6-420E-8234-E1A7770CDDD9Q33810991-44E7DCEA-FAAA-46FB-806B-E3853EF3BBB1Q33844196-BE063A20-911A-40E1-BAED-241D29F82A61Q34409114-9E0ED35E-FF71-4154-A7CF-D082012963B1Q34508830-186FA0F8-18E4-4F44-8F4E-CFD402E21C87Q35191379-C318B3B3-7299-4C1F-8776-F93F196A710CQ35192162-8174556C-3047-4095-AD71-02F15E4513B5Q35273580-E3569DE6-ECC5-4900-AB24-88A06D4D3A52Q35692337-76697B0D-615A-45B7-93AA-19DB8DF1CAE9Q36357419-DF68E1B4-8BF2-47F6-BC43-D4AB495E5DE2Q37205675-89863441-E2FE-4C76-948D-BCDEE4BF7C62Q37273653-3BBE69D7-B9FA-40BC-8CF1-902BF45C57D8Q37340339-F6CA5A2E-A56C-4D9D-8040-A366AA2AB873Q38182087-CB474D79-3E68-44FC-A92F-6F914116D1A4Q38235943-FC09899C-233B-4365-A8B5-4ED9C512F9C0Q38238745-03DEA460-222D-4BA1-A80E-D5CB4DB6FEB7Q38424698-E872A9B0-8AFE-4734-B1B2-9787A1E2C362Q39503264-44EEFBD5-8018-431D-B8F3-702AB3773471Q39588933-9E9C669B-8104-4BCE-9F08-B228E023F798Q39907949-185BAA61-0363-4FD8-83A5-95216E274C96Q40957363-A2249870-9DF5-481A-A54D-AA1531F19D16Q41807465-D6A804FA-D4B9-4CD2-B2E5-87B88D8BC5A1Q42129420-A98A3FA2-78CA-4F82-B9B9-5B0949FD1652Q43218781-81546F47-4ABD-46D0-8436-10031DD1D203Q44790817-5FB9DDFF-D36B-469A-94D6-C4435DCB6E98Q46425018-22CE2FC2-5C03-4FA5-9353-5615B3734CE4Q51008107-2265C34A-13DA-4F22-A1B3-09E3347198BB
P2860
The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The relationship between previ ...... Helicobacter pylori infection.
@en
The relationship between previ ...... Helicobacter pylori infection.
@nl
type
label
The relationship between previ ...... Helicobacter pylori infection.
@en
The relationship between previ ...... Helicobacter pylori infection.
@nl
prefLabel
The relationship between previ ...... Helicobacter pylori infection.
@en
The relationship between previ ...... Helicobacter pylori infection.
@nl
P2093
P356
P1476
The relationship between previ ...... Helicobacter pylori infection.
@en
P2093
Alan J Parkinson
Alisa L Reasonover
Brian J McMahon
Debby A Hurlburt
John J Carothers
John M Coleman
Julie M Morris
Michael Bensler
Michael G Bruce
P356
10.1086/510074
P407
P577
2006-12-07T00:00:00Z